Immune monitoring summary and clinical outcomes of patients who produced a measureable immune response
| Dose (mg) | Patient | HLA Type | HLA/A*0101 Tetramer+ | CD8+ IFNγ+ | Phenotype Tetramer+CD8+T cells* |
|---|---|---|---|---|---|
| 0.2 | Tyr-1 | A0101 | - | - | |
| Tyr-2 | A1101 | ND | - | ||
| Tyr-3 | A01 | ND | - | ||
| 0.5 | Tyr-4 | A0101 | - | - | |
| Tyr-5 | A0101 | - | - | ||
| Tyr-6 | A2501 | ND | - | ||
| 1.5 | Tyr-8 | A2402 | ND | - | |
| Tyr-9 | A0101 | + | - | CCR7low,CD45RAlow, CD27int, CD28int | |
| Tyr-11 | A0101 | - | - | ||
| Tyr-12# | A02 | ND | ND | ||
| Tyr-13 | A2402 | ND | - | ||
| Tyr-14 | A0301/A2402 | ND | - | ||
| Tyr-16# | A0101 | ND | ND | ||
| Tyr-18 | A0101 | - | - | ||
| Tyr-19 | A0101 | - | - | ||
| Tyr-20# | A0101 | ND | ND | ||
| Tyr-21 | A03 | ND | - | ||
| Tyr-22 | A0101 | - | - | ||
| Tyr-23 | A0101 | - | - | ||
| Tyr-24 | A0101 | - | + | ||
| Tyr-25 | A0101 | - | + | ||
| Tyr-26 | A0101 | + | + | CCR7low,CD45RAlow, CD27int, CD28low | |
| Tyr-27 | A0101 | + | - | CCR7low,CD45RAlow, CD27int, CD28int | |
| Tyr-28 | A0101 | + | - | CCR7low,CD45RAlow, CD27int, CD28int |
* Low = 0–30%, intermediate (int) =30–60%, and high = 60–100% of cells that are tetramer positive. # Patient Tyr-12, 16 and 20 did not finish vaccine protocol. ND = not done. “+” = Patients scored positive for tetramer-reactive CD8+ T cell or Tyr-reactive CD8+IFN-γ+ T cell response; “-” = Patients scored negative for tetramer-reactive CD8+ T cell or Tyr-reactive CD8+IFN-γ+ T cell response.